综述:哮喘和慢性阻塞性肺疾病中的胃食管反流病
本文综述胃食管反流病(GERD)在哮喘和慢性阻塞性肺疾病(COPD)中的作用。哮喘患者GERD患病率估计为30%至90%,对照组平均为24%;COPD患者GERD患病率为19%至78%,对照组平均为18%。数据提示哮喘和COPD患者GERD患病率增加,但因果关系未确立,抗反流治疗对肺部结局的影响不一致且相互矛盾。
要点
- 哮喘患者GERD患病率30%至90%,对照组平均24%。
- COPD患者GERD患病率19%至78%,对照组平均18%。
- 文献支持GERD是COPD急性加重的危险因素及「频繁加重者」表型的预测因素。
核心结论
- 尽管哮喘和COPD中GERD患病率高,但缺乏因果联系。
- 抗反流治疗对肺部结局的结果不一致且相互矛盾。
- 未来研究需识别可能从抗反流治疗中获益的哮喘和COPD患者亚组(夜间或沉默性反流)。
研究设计与样本
- 通过PubMed检索相关文章,关键词为GERD、哮喘、COPD、患病率、治疗;排除病例报告,仅考虑英文文献。
主要发现
- 哮喘患者GERD患病率估计为30%至90%,对照组平均为24%。
- COPD患者GERD患病率为19%至78%,对照组平均为18%。
- 数据提示哮喘和COPD患者GERD患病率增加,但因果关系未确立,GERD治疗效果不一致。
- 文献支持GERD作为COPD急性加重的危险因素和「频繁加重者」表型的预测因素。
局限性
- 因果关系未确立。
- GERD治疗的效果不一致。
- 抗反流治疗对肺部结局的结果不一致且相互矛盾。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: When gastro-oesophageal reflux is causing symptoms or lesions in the oesophagus, this is referred to as gastro-oesophageal reflux disease (GERD). GERD can manifest itself through typical symptoms (heartburn, regurgitation) or may lead to extra-oesophageal symptoms. Extra-oesophageal manifestations of GERD gained increasing attention over the last decade, especially respiratory disorders, because of the prevalent co-occurrence with GERD. The role of GERD in the pathogenesis of respiratory disorders has become a topic of intense discussion. AIM: To provide an overview of the current knowledge on the role of GERD in asthma and chronic obstructive pulmonary disease (COPD). METHODS: PubMed was searched for relevant articles using the keywords: GERD, asthma, COPD, prevalence, treatment. Case reports were excluded, only English language articles were considered. RESULTS: Estimates for the prevalence of GERD in asthma range from 30% to 90%, compared to an average of 24% in controls. In COPD patients, the prevalence of GERD ranges from 19% to 78% compared to an average of 18% in controls. These data indicate an increased prevalence of GERD in patients with asthma and COPD, although causality is not established and GERD treatment yielded inconsistent effects. Literature supports GERD as a risk factor for COPD-exacerbations and a predictor of the 'frequent-exacerbator'-phenotype. CONCLUSIONS: Despite the high prevalence of GERD in asthma and COPD, a causal link is lacking. The results of anti-reflux therapy on pulmonary outcome are inconsistent and contradictory. Future studies will need to identify subgroups of asthmatics and COPD patients that may benefit from anti-reflux therapy (nocturnal or silent reflux).
引用
- Broers C, Tack J, Pauwels A, et al. Review article: gastro-oesophageal reflux disease in asthma and chronic obstructive pulmonary disease. Aliment Pharmacol Ther. 2017. PMID: 29193245. doi:10.1111/apt.14416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。